Dana-Farber Cancer Institute | Strategic Alliance Partners

June 22, 2021

Giada Bianchi, MD, discusses diagnostic factors for light chain amyloidosis.

June 22, 2021

Judy Garber, MD, MPH, discusses the efficacy of adjuvant olaparib in patients with high-risk, HER2-negative breast cancer, as demonstrated in the phase 3 OlympiA trial.

June 21, 2021

Omar Nadeem, MD, discusses the emergence of quadruplet regimens in multiple myeloma.

June 21, 2021

The expanding therapeutic landscape in multiple myeloma is poised to integrate daratumumab-based quadruplet therapies and novel cellular therapies as standard options for patients with newly diagnosed and relapsed/refractory disease.

June 17, 2021

Adam Sperling, MD, PhD, discusses the rationale to evaluate cellular therapy in multiple myeloma.

June 15, 2021

Atish D. Choudhury, MD, PhD, discusses emerging treatment strategies in metastatic castration-resistant prostate cancer.

June 10, 2021

Although circulating tumor cell analysis of patients with HER2-negative metastatic breast cancer identified patients with CTC amplification, the utility of subsequent HER2-directed treatment with trastuzumab plus vinorelbine in this patient population was low.

June 07, 2021

Dr. Munshi discusses the significance of the FDA approval of ide-cel in relapsed/refractory multiple myeloma, data from the KarMMa trial, which served as the basis for the approval, and next steps for CAR T-cell therapy in the field.

May 25, 2021

James A. DeCaprio, MD, discusses raising awareness in Merkel cell carcinoma.

May 17, 2021

Despite a modest central nervous system overall response rate, the combination of pertuzumab and high-dose trastuzumab was found to induce clinical benefit in 68% of patients with HER2-positive metastatic breast cancer enrolled to the phase 2 PATRICIA trial.

May 13, 2021

Nikhil C. Munshi, MD, discusses how idecabtagene vicleucel has potentially marked the beginning of a new chapter for cellular therapy in multiple myeloma.

May 12, 2021

Guru P. Sonpavde, MD, discusses anticipated data in bladder cancer.

April 26, 2021

Atish D. Choudhury, MD, PhD, discusses future research directions for the combination of pembrolizumab and radium-223 dichloride in patients with metastatic castration-resistant prostate cancer.

April 22, 2021

The plethora of actionable targets in intrahepatic cholangiocarcinoma has created opportunities for these patients to be treated with targeted therapy.

April 15, 2021

Dr. Sonpavde discusses key data presented during the 2021 Genitourinary Cancers Symposium in urothelial carcinoma and anticipated research directions with immunotherapy, chemotherapy, and antibody-drug conjugates.

April 05, 2021

In our exclusive interview, Dr. Choueiri and Dr. Motzer discuss the clinical implications of the phase 3 CheckMate-9ER trial in advanced renal cell carcinoma and how to best use the combination in practice.

March 30, 2021

Narjust Duma, MD, has been named as the new associate director of the Cancer Care Equity Program at the Dana-Farber Cancer Institute, as well as an assistant professor of medicine at Harvard Medical School.

March 29, 2021

Nikhil C. Munshi, MD, discusses the FDA approval of idecabtagene vicleucel for patients with relapsed/refractory multiple myeloma after 4 or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.

March 20, 2021

Dostarlimab plus niraparib and bevacizumab showcased favorable antitumor activity and tolerability in patients with platinum-resistant ovarian cancer.

March 11, 2021

Paul G. Richardson, MD, discusses the toxicity profile of melphalan flufenamide in relapsed/refractory multiple myeloma.